reference/29493544

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29493544

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Comparative Study\|Journal Article\|Randomized Controlled Trial
endingPage	479
issn	1042-8194 1029-2403
issueIdentifier	3
pageRange	473-479
publicationName	Leukemia & Lymphoma
startingPage	473
bibliographicCitation	Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk Lymphoma. 2006 Mar;47(3):473–9. doi: 10.1080/10428190500312295. PMID: 16396771.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e74d53c43378236ef7fa278d60b0b8b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3507cd7dd37b74ff4a8160cd04987a67 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3260e6496bd5c7714d61f149e9dbf7b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8bd219c731a69bf5efed67c78fb2720 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd023fbe62d76f2ac212e563fa9d1cfa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b77b292d64d35d36ce00c0adad34ba4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_136a74766836d23c155b70fca61a61f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a4d562d49bf4d7a66a63fd988ef7909 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6bf3d176bf27d3baed9fc02564a17ce7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_315c1eab56b747ac290ee407b92193c1
date	200601
identifier	https://doi.org/10.1080/10428190500312295 https://pubmed.ncbi.nlm.nih.gov/16396771
isPartOf	https://portal.issn.org/resource/ISSN/1042-8194 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2306 https://portal.issn.org/resource/ISSN/1029-2403
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by theGruppo Italiano per lo Studio dei Linfomi
discusses	http://id.nlm.nih.gov/mesh/M0017616 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0097344 http://id.nlm.nih.gov/mesh/M0022672 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M000754277
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014747Q000031 http://id.nlm.nih.gov/mesh/D008228Q000628 http://id.nlm.nih.gov/mesh/D011344Q000008 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D016879 http://id.nlm.nih.gov/mesh/D003841Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D012074 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D008228Q000473 http://id.nlm.nih.gov/mesh/D012008 http://id.nlm.nih.gov/mesh/D014747Q000009 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D011241Q000009 http://id.nlm.nih.gov/mesh/D014747Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D003131 http://id.nlm.nih.gov/mesh/D000077235 http://id.nlm.nih.gov/mesh/D014182 http://id.nlm.nih.gov/mesh/D033581 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011344Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73265388 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13200033 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60780 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44424639 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46931011 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311497 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4915 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5672 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71296871

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136123131

Total number of triples: 83.